5 614.51 PTS
-0.13 %
5 546.0
-0.23 %
SBF 120 PTS
4 475.40
-0.15 %
DAX PTS
13 077.72
-0.28 %
Dowjones PTS
24 715.09
+0.00 %
6 866.25
-0.51 %
Nikkei PTS
22 930.36
+0.40 %

DBV Technologies to Attend Upcoming Investor Conferences

| GlobeNewswire | 432 | Aucun vote sur cette news
DBV Technologies to Attend Upcoming Investor Conferences
Credits  ShutterStock.com

Press Release
Montrouge, France, February 1, 2018

DBV Technologies to Attend Upcoming Investor Conferences

                                                                                                                                                                               

DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced that members of its management team will present and host investor meetings at the following investor conferences in February 2018:

Susanna Mesa, Chief Business Officer, will present at the LEERINK Partners 7th Annual Global Healthcare Conference in New York, NY, on Wednesday, February 14, 2018, at 3:00pm EST.

Charles Ruban, Chief Operating Officer, will present at the 2018 RBC Capital Markets Global Healthcare Conference in New York, NY, on Thursday, February 22, 2018, at 11:00am EST.

A live webcast of the Company's presentations at the LEERINK and RBC conferences will be available on the Investor Relations section of the Company's website: http://www.dbv-technologies.com/en/investor-relations. Replays of the presentation will also be available on DBV's website within 48 hours after the events.

 

About DBV Technologies 

DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com

 

DBV Investor Relations Contact

Sara Blum Sherman

Senior Director, Investor Relations & Strategy
+1 212-271-0740
sara.sherman@dbv-technologies.com

 

DBV Media Contact

Roberta Di Giorgio

Senior Director, Corporate Communications
+1 917-612-2861
roberta.digiorgio@dbv-technologies.com

 


Copyright GlobeNewswire

Les annexes de ce communiqué sont disponibles à partir de ce lien :
http://hugin.info/156437/R/2165277/833116.pdf

Information réglementaire
Ce communiqué de presse est diffusé par Nasdaq Corporate Solutions. L'émetteur est seul responsable du contenu de ce communiqué.



 ■
Les recommandations diffusées sur le site Bourse Direct sont des recommandations d'investissement à caractère général soumises aux dispositions législatives et réglementaires applicables aux communications à caractère promotionnel. Elles ne constituent en aucun cas un conseil personnalisé. Le client reconnaît et assure donc seul la responsabilisé de ses actes de gestion et des conséquences des positions prises ou non.
Votez pour cet article
0 avis
Note moyenne : 0
  • 0 vote
  • 0 vote
  • 0 vote
  • 0 vote
  • 0 vote

ÉVÈNEMENT

IMMERSION EXCLUSIVE AU COEUR DE LA BOURSE
DU 28 MAI AU 1erJUIN 2018

EN PARTENARIAT AVEC

INSCRIVEZ-VOUS DÈS MAINTENANT ! Cliquez ici

À LIRE AUSSI SUR BOURSE DIRECT
Publié le 18/05/2018

Communiqué Financier Paris, le 18 mai 2018       IT LINK : 10,9 MEUR de chiffre d'affaires au T1       En MEUR T1 2017  T1…

Publié le 18/05/2018

Nexans Siège Social : 4 allée de l'Arche, 92400 Courbevoie, FranceTél : + 33 (0) 1 78 15 00 00 - www.nexans.comS.A. au capital de 43 494 691 euros…

Publié le 18/05/2018

L'Assemblée générale des actionnaires d'Elis présidée par Thierry Morin, Président du Conseil de Surveillance, a approuvé les comptes annuels et consolidés de l'exercice 2017 et la…

Publié le 18/05/2018

60 millions d'euros seront investis dans le cadre de ce plan